Climb Bio Inc (CLYM) - Total Liabilities
Based on the latest financial reports, Climb Bio Inc (CLYM) has total liabilities worth $4.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Climb Bio Inc to track the company's year-over-year net asset growth rate.
Climb Bio Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Climb Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See Climb Bio Inc (CLYM) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Climb Bio Inc Competitors by Total Liabilities
The table below lists competitors of Climb Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coastal Financial Corp
NASDAQ:CCB
|
USA | $5.16 Billion |
|
Team Group Inc
TW:4967
|
Taiwan | NT$14.80 Billion |
|
YaGuang Technology Group Co Ltd
SHE:300123
|
China | CN¥3.25 Billion |
|
Warteck Invest Ltd
SW:WARN
|
Switzerland | CHF554.35 Million |
|
Feitian Technologies Co Ltd
SHE:300386
|
China | CN¥135.24 Million |
|
Ciputra Development Tbk
JK:CTRA
|
Indonesia | Rp18.34 Trillion |
|
Sido Muncul PT
JK:SIDO
|
Indonesia | Rp386.74 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$22.86 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Climb Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Climb Bio Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 27.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Climb Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Climb Bio Inc (2019–2025)
The table below shows the annual total liabilities of Climb Bio Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.27 Million | +37.00% |
| 2024-12-31 | $5.31 Million | +84.88% |
| 2023-12-31 | $2.87 Million | -54.28% |
| 2022-12-31 | $6.28 Million | +3.96% |
| 2021-12-31 | $6.04 Million | +97.13% |
| 2020-12-31 | $3.06 Million | +291.19% |
| 2019-12-31 | $783.00K | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more